Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EX 101 - Guangzhou Excelmab

Next Previous
Drug Profile

EX 101 - Guangzhou Excelmab

Alternative Names: EX-101 - Guangzhou Excelmab

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Guangzhou Excelmab
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 May 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in China (Injection)
  • 20 Sep 2023 Guangzhou ExcelMab plans a phase III trial of EX 101 for Breast cancer and Gastric cancer in USA and China, in the first quarter of 2025 (Guangzhou ExcelMab pipeline, September 2023)
  • 11 Sep 2023 Guangzhou ExcelMab announces intention to submit BLA of EX 101 for Breast cancer and Gastric cancer in USA and China, in 2025 (Guangzhou ExcelMab pipeline, September 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top